Centre for Infectious Diseases and Microbiology, The Westmead Institute for Medical Research, Sydney, NSW, Australia.
Sydney Medical School-Westmead, The University of Sydney, Sydney, NSW, Australia.
Front Cell Infect Microbiol. 2019 Jul 15;9:248. doi: 10.3389/fcimb.2019.00248. eCollection 2019.
Invasive fungal pathogens cause more than 300 million serious human infections and 1.6 million deaths per year. A clearer understanding of the mechanisms by which these fungi cause disease is needed to identify novel targets for urgently needed therapies. Kinases are key components of the signaling and metabolic circuitry of eukaryotic cells, which include fungi, and kinase inhibition is currently being exploited for the treatment of human diseases. Inhibiting evolutionarily divergent kinases in fungal pathogens is a promising avenue for antifungal drug development. One such group of kinases is the phospholipase C1-dependent inositol polyphosphate kinases (IPKs), which act sequentially to transfer a phosphoryl group to a pre-phosphorylated inositol sugar (IP). This review focuses on the roles of fungal IPKs and their IP products in fungal pathogenicity, as determined predominantly from studies performed in the model fungal pathogen , and compares them to what is known in non-pathogenic model fungi and mammalian cells to highlight potential drug targeting opportunities.
侵袭性真菌病原体每年导致超过 3 亿例严重的人类感染和 160 万人死亡。为了确定急需治疗的新型靶点,需要更清楚地了解这些真菌引起疾病的机制。激酶是真核细胞(包括真菌)信号转导和代谢电路的关键组成部分,激酶抑制目前正被用于治疗人类疾病。抑制真菌病原体中进化上有差异的激酶是开发抗真菌药物的一个有前途的途径。这样的激酶组之一是磷脂酶 C1 依赖性肌醇多磷酸激酶 (IPK),它们依次作用将磷酸基团转移到预磷酸化的肌醇糖 (IP)上。这篇综述主要关注真菌 IPK 及其 IP 产物在真菌致病性中的作用,这些作用主要是通过在模型真菌病原体中进行的研究确定的,并将其与非致病性模型真菌和哺乳动物细胞中的已知作用进行比较,以突出潜在的药物靶标机会。